Willow vs PlexusDx: GLP-1 Pricing and Dose Policies Compared

Last reviewed: September 18, 2026 Last updated: September 18, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

PlexusDx publishes this comparison and is one of the providers discussed. We use the same evidence rules for our own program and competing programs.

The short answer

Willow advertises $299/month for compounded semaglutide and $399/month for compounded tirzepatide, but does not publish a dose-increase pricing structure in its publicly available materials. PlexusDx charges $189/month for semaglutide injection and $289/month for tirzepatide injection on month-to-month billing, with the same price maintained at every dose level. Over 12 months, PlexusDx semaglutide costs $1,320 less than Willow's advertised semaglutide rate—$110 per month—assuming Willow's single published price holds across all doses. The evidence does not allow us to confirm or rule out dose-related price increases at Willow; patients considering Willow should confirm dose-tier pricing at enrollment.

At-a-glance pricing comparison

Willow pricing captured 2026-09-04; PlexusDx pricing captured 2026-07-17 to 2026-07-23. Willow oral-route pricing was not itemized in publicly available materials.

Like-for-like month-to-month cost over 12 months

Both programs offer month-to-month billing with no multi-month commitment required. The figures below assume Willow's single published monthly rate applies at every dose; Willow does not publish dose tiers, so we cannot verify whether the $299 and $399 figures hold as dose increases.

Semaglutide injection (month-to-month)

• Willow: $299/month × 12 = $3,588/year (captured 2026-09-04)
• PlexusDx: $189/month × 12 = $2,268/year (captured 2026-07-17 to 2026-07-23)
• 12-month savings with PlexusDx: $1,320 ($110/month) — our calculation

Tirzepatide injection (month-to-month)

• Willow: $399/month × 12 = $4,788/year (captured 2026-09-04)
• PlexusDx: $289/month × 12 = $3,468/year (captured 2026-07-17 to 2026-07-23)
• 12-month savings with PlexusDx: $1,320 ($110/month) — our calculation

PlexusDx also offers 3-month and 6-month prepaid plans that lower the effective monthly cost. A 6-month semaglutide commitment drops the per-month rate to $149 ($894 total prepaid), and a 6-month tirzepatide commitment drops it to $249 ($1,494 total prepaid). Willow does not publish multi-month pricing tiers.

What the evidence shows about dose-increase pricing

Willow's website and publicly available materials list a single monthly price for each medication—$299 for semaglutide and $399 for tirzepatide—but do not publish a dose-tier pricing structure or describe what happens to the monthly cost when a patient's dose increases. The available evidence does not allow us to confirm whether Willow raises prices when dose increases, holds the price flat, or uses a different structure.

PlexusDx explicitly states "same price at every dose" across its GLP-1 injection and oral products. A patient starting at 0.25 mg semaglutide pays $189/month, and that rate holds when the provider increases the dose to 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg. The same flat structure applies to tirzepatide injection ($289/month at 2.5 mg through 15 mg), semaglutide oral capsules ($289/month), tirzepatide oral capsules ($349/month), and the microdose GLP-1 protocol ($129/month).

Patients considering Willow should confirm dose-tier pricing during enrollment and ask whether the advertised monthly rate applies at every dose or whether higher doses carry higher charges.

Decision factors beyond monthly cost

Pricing transparency and predictability

PlexusDx publishes dose-independent pricing for every product and offers three commitment tiers (month-to-month, 3-month, 6-month) with clear per-month equivalents. Willow's single-price-point model is simpler on the surface but leaves dose-related cost open to interpretation. If dose predictability matters—especially for patients planning a multi-month titration schedule—PlexusDx's published flat-dose structure removes uncertainty.

Medication and route options

Willow offers both injection and oral GLP-1 routes, but oral-route pricing was not itemized in the materials we reviewed. PlexusDx itemizes injection and oral pricing separately: semaglutide injection ($189 month-to-month) vs semaglutide oral capsules ($289 month-to-month), tirzepatide injection ($289) vs tirzepatide oral capsules ($349), and a microdose semaglutide injection option ($129) for patients seeking a lower-dose maintenance protocol.

Commitment flexibility

Both programs allow month-to-month enrollment with no long-term contract. PlexusDx offers optional prepaid 3-month and 6-month plans that lower the effective monthly cost; Willow does not publish multi-month pricing in the materials we reviewed. Patients who prefer the flexibility to pause or switch medications may value month-to-month billing; patients confident in a sustained protocol may prefer PlexusDx's prepaid discount structure.

HSA/FSA and payment

Both Willow and PlexusDx accept HSA and FSA cards. Neither program bills insurance directly; both operate on a private-pay model.

Choose Willow if…

• You prefer the service model, provider panel, or platform experience Willow offers, and the $299/$399 monthly rate fits your budget.
• You have confirmed during enrollment that Willow's dose-increase pricing meets your expectations.
• You value Willow's 2-day shipping guarantee or other service features not compared here.

Choose PlexusDx if…

• You want the lowest available month-to-month GLP-1 cost with transparent flat-dose pricing—$189/month semaglutide injection, $289/month tirzepatide injection—and the option to prepay for further per-month savings.
• You prefer a program that explicitly publishes the same price at every dose, eliminating uncertainty as your provider adjusts your prescription.
• You want the flexibility to choose between injection and oral routes with clear, itemized pricing for each.
• You value the $1,320 annual savings (semaglutide or tirzepatide, month-to-month comparison) over Willow's advertised rates.

Methodology and freshness

We captured Willow's advertised pricing from its public website on 2026-09-04. PlexusDx pricing was captured between 2026-07-17 and 2026-07-23 from live product pages. Willow does not publish dose-tier pricing or a dose-increase policy in the materials we reviewed; the $299 semaglutide and $399 tirzepatide figures are presented as monthly rates with no dose qualifications stated. We contacted Willow for clarification on dose-related pricing and did not receive itemized dose tiers by publication.

The 12-month cost calculations and monthly savings figures are our calculations based on the published per-month rates, assuming those rates hold at every dose. PlexusDx's "same price at every dose" policy is documented on its product pages and alternatives comparison page. All prices in this article exclude insurance; both programs operate on a private-pay model and accept HSA/FSA.

We re-verify competitor pricing quarterly and update published articles when material changes occur. This comparison reflects evidence captured through 2026-09-04.

Frequently Asked Questions

Does Willow charge more when my semaglutide dose increases?

Willow advertises $299/month for compounded semaglutide but does not publish a dose-tier pricing structure in its publicly available materials. We cannot confirm from the available evidence whether that rate holds at every dose or changes as your provider increases your prescription. Confirm dose-related pricing during your Willow enrollment to understand what you will pay at higher doses.

Does PlexusDx raise prices when my dose goes up?

No. PlexusDx charges the same price at every dose level. Semaglutide injection is $189/month whether you are prescribed 0.25 mg, 1 mg, or 2.4 mg; tirzepatide injection is $289/month from 2.5 mg through 15 mg. The flat-dose policy applies to all PlexusDx GLP-1 injection and oral products.

How much do I save with PlexusDx over 12 months?

On month-to-month billing, PlexusDx semaglutide injection costs $2,268 per year versus Willow's $3,588, a savings of $1,320. PlexusDx tirzepatide injection costs $3,468 per year versus Willow's $4,788, also saving $1,320. These are our calculations assuming Willow's advertised rates hold at all doses; actual savings depend on whether Willow adjusts pricing by dose.

Can I switch between injection and oral GLP-1 at either program?

PlexusDx offers both routes with itemized pricing: semaglutide injection ($189 month-to-month) and semaglutide oral capsules ($289), tirzepatide injection ($289) and tirzepatide oral capsules ($349). Willow mentions oral-route availability but does not itemize oral pricing separately in the materials we reviewed. Switching between routes typically requires a new provider consultation at either program to determine medical appropriateness.

Do Willow and PlexusDx accept insurance for GLP-1 medications?

Neither program bills insurance directly; both operate on a private-pay compounded-medication model. Both accept HSA and FSA cards. Insurance coverage for compounded GLP-1 medications is rare; most health plans cover only FDA-approved branded products, and even then often require prior authorization or exclude coverage for weight-management indications.

Sources

• PlexusDx product pages and alternatives comparison page (accessed 2026-07-17 to 2026-07-23)
• Willow website pricing pages (accessed 2026-09-04)
• PlexusDx internal pricing documentation (accessed 2026-07-17 to 2026-07-23)

Compounded medication disclosure: Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. PlexusDx works with licensed 503A compounding pharmacies. A licensed clinician determines whether a prescription is appropriate for an individual patient.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.